{"id":382644,"date":"2020-11-17T07:03:16","date_gmt":"2020-11-17T12:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382644"},"modified":"2020-11-17T07:03:16","modified_gmt":"2020-11-17T12:03:16","slug":"autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","title":{"rendered":"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON, Nov.  17, 2020  (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>1<\/strong><br \/>\n          <strong>9<\/strong><br \/>\n          <strong> November 2020<\/strong>\u00a0\u2013\u00a0Dr.\u00a0Christian Itin, chairman and chief executive officer, will participate in an analyst led fireside chat and host virtual one-on-one meetings at the Jefferies Virtual London Healthcare Conference at 11.25 pm ET, 4.25 pm GMT. A live audio webcast of the fireside chat will be available on the investor relations section of the Company\u2019s website at <a href=\"https:\/\/www.autolus.com\/investor-relations\/news-and-events\/events\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Auto<\/a><a href=\"https:\/\/www.autolus.com\/investor-relations\/news-and-events\/events\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">l<\/a><a href=\"https:\/\/www.autolus.com\/investor-relations\/news-and-events\/events\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">us<\/a>. An archived replay will be available for a period of 30 days after the conference.<\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>7<\/strong><br \/>\n          <strong> December <\/strong><br \/>\n          <strong>2020<\/strong> \u2013 Dr. Christian Itin, chairman and chief executive officer, along with the Autolus clinical team, will host an investor call and webcast at 4.00 pm ET, 9.00 pm GMT to discuss presentations related to its AUTO1 and AUTO3 programs, the company\u2019s CAR T cell therapies being investigated in adult Acute Lymphoblastic Leukemia (ALL) and relapsed\/ refractory diffuse large B cell lymphoma (DLBCL), respectively, during the ASH conference. To listen to the webcast and view the accompanying slide presentation, please go to <a href=\"https:\/\/www.autolus.com\/investor-relations\/news-and-events\/events\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Autolus<\/a>. After the conference call, a replay will be available for a period of one week.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Autolus Therapeutics plc<\/strong>\n      <\/p>\n<p align=\"justify\">Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.<\/p>\n<p align=\"justify\">\n        <strong>Contact: <\/strong>\n      <\/p>\n<p align=\"justify\">Lucinda Crabtree, PhD<br \/>Vice President, Investor Relations and Corporate Communications<br \/>+44 (0)\u00a07587 372 619\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FYq9Z5LQhBCBnj2Mbk66GhDO8DsM3ACqgX6AYjTEVws_EOOi690pIPpbyjNvmW6RGmOvDDwT53mV7Wyzl7w3xNVfJtpYvCLORXA0KtQfsBU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">l.crabtree@autolus.com<\/a><\/p>\n<p align=\"justify\">Julia Wilson<br \/>+44 (0) 7818 430877<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-FF9zjMDZCHE-ekmkJwDhOQefzCnubsS3lEREgJ-j9y7Fc4F06miuBId4GFQb35XJytLYczpBz1QD2Eahqt4lks98NukQYnXb0WVb3OCVOc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">j.wilson@autolus.com<\/a><\/p>\n<p align=\"justify\">Susan A. Noonan<br \/>S.A. Noonan Communications<br \/>+1-212-966-3650<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UCcGef2rABM6A2Q0iPd6OKnC1geRrOKioEir-0OITjHBM02QVyJOI8DILhGPiGzf7TUAoqMRzy_hLL1SfAQ9siJPcRmbYOv9dTADELoh5mk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">susan@sanoonan.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c8978741-55e1-4c9c-abc0-3fb11d955216\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference: 1 9 November 2020\u00a0\u2013\u00a0Dr.\u00a0Christian Itin, chairman and chief executive officer, will participate in an analyst led fireside chat and host virtual one-on-one meetings at the Jefferies Virtual London Healthcare Conference at 11.25 pm ET, 4.25 pm GMT. A live audio webcast of the fireside chat will be available on the investor relations section of the Company\u2019s website at Autolus. An archived replay will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382644","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference: 1 9 November 2020\u00a0\u2013\u00a0Dr.\u00a0Christian Itin, chairman and chief executive officer, will participate in an analyst led fireside chat and host virtual one-on-one meetings at the Jefferies Virtual London Healthcare Conference at 11.25 pm ET, 4.25 pm GMT. A live audio webcast of the fireside chat will be available on the investor relations section of the Company\u2019s website at Autolus. An archived replay will &hellip; Continue reading &quot;Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T12:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference\",\"datePublished\":\"2020-11-17T12:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"wordCount\":371,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"name\":\"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=\",\"datePublished\":\"2020-11-17T12:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","og_description":"LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference: 1 9 November 2020\u00a0\u2013\u00a0Dr.\u00a0Christian Itin, chairman and chief executive officer, will participate in an analyst led fireside chat and host virtual one-on-one meetings at the Jefferies Virtual London Healthcare Conference at 11.25 pm ET, 4.25 pm GMT. A live audio webcast of the fireside chat will be available on the investor relations section of the Company\u2019s website at Autolus. An archived replay will &hellip; Continue reading \"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T12:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference","datePublished":"2020-11-17T12:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"wordCount":371,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","name":"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=","datePublished":"2020-11-17T12:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzYxNCMzODMxMzc0IzIxMTA0Mjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382644"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382644\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}